Cibisatamab (CD3E/CEACAM5) Antibody, Monoclonal
Code | Size | Price |
---|
PSI-10-880-0.1mg | 0.1mg | £657.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Isotype: IgG1-kappa/lambda with domain crossover
Antibody Clonality: Recombinant Antibody
Regulatory Status: RUO
Shipping:
blue ice
Storage:
Store at -80˚C
Images
Documents
Further Information
Additional Names:
CEA TCB,RG-7802,RO-6958688
Background:
Cibisatamab (CEA-TCB) is T cell bispecific antibody that binds to carcinoembryonic antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab has one single CD3 epsilon chain binding site and two CEA binding sites on T cells (which regulates the binding affinity to cancer cells with high expression of CEA on the cell surface). This avoids targeting healthy epithelial cells with low CEA expression levels. T cell activation is triggered by binding to CEA on the surface of cancer cells and CD3 on T cells, cytokine secretion and release of cytotoxic particles.
Buffer:
PBS buffer pH7.5
Concentration:
batch dependent
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
Humanized / CD3E/CEACAM5 [Homo sapiens]
NCBI Organism:
homo sapiens
Purification:
>95%
Research Area:
Drug Analogues
Source:
CHO cells
User NOte:
Optimal dilutions for each application to be determined by the researcher.